To resolve the contribution of CD19 splicing in CART-19 therapy, we re-analysed RNA-seq data from Orlando and co-workers5, in which B-ALL cells of 17 patients were sequenced at initial screening and after relapse. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.